Closed · W81XWH-22-PRARP-ADRA · CFDA 12.420 · Discretionary
DoD Peer Reviewed Alzheimer’s Research Program, Accelerating Diagnostics Research Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- July 25, 2022
- Close date
- 2
- Expected awards
The verdict
DoD Peer Reviewed Alzheimer’s Research Program, Accelerating Diagnostics Research Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 2 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 2
- expected awards
- 12.420
- CFDA program
Archived opportunity record
DoD Peer Reviewed Alzheimer’s Research Program is closed (last close July 25, 2022). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed July 25, 2022
Est. Total Funding
$5,000,000
Expected Awards
2
Instrument
Grant
Description
The intent of the FY22 PRARP ADRA is to support high-impact advancement of robust diagnostic and/or prognostic factors pertaining to AD/ADRD following military service and/or TBI. Applications meeting the intent of this mechanism will accelerate clinically useful factors for rapid transfer to clinical practice to bridge a critical gap between identification of relevant factors and clinical usage. The proposed factors for investigation must correlate with clinical endpoints relevant to AD/ADRD following military service and/or TBI. Inclusion of preliminary data is required. Applicants should clearly describe the intent, purpose, as well as the clinical and practical utility of the diagnostic and/or prognostic factors being studied. Considerations for how the diagnostic/prognostic factors meaningfully inform care and disease management should be described both at the provider and individual living with AD/ADRD level. As part of the application, the proposed prognostic or diagnostic factors should demonstrate their potential for improved specificity and sensitivity with respect to diagnosis and/or prognosis of AD/ADRD as the study endpoint. Additionally, applications should address the utility of the diagnostic/ prognostic factor(s) in rural or resource-limited environments. Applications may consider elements of biomarker and risk factor validation as part of the application, particularly if validation is intended to widen the diversity of the population to which the factors/biomarkers will be applicable. Biomarker validation is defined as assessing the biomarker’s measurement performance characteristics in terms of reproducibility, accuracy, precision, and limits of sensitivity. Risk factors may include modifiable and non-modifiable factors that influence a person’s likelihood to develop AD/ADRD. Clinical trials are not allowed; however, the FY22 ADRA may use data and/or human anatomical substances from an existing clinical trial to carry out the research.
Catch-all / unrestricted eligibility mark · W81XWH-22-PRARP-ADRA
Grants.gov marks DoD Peer Reviewed Alzheimer’s Research Program with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoD Peer Reviewed Alzheimer’s Research Program is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |